Can I Take N-Acetylcysteine (NAC) with Finasteride?

How Finasteride Works in the Body

Finasteride is a selective, competitive inhibitor of 5-alpha-reductase type II, the enzyme that converts testosterone into dihydrotestosterone (DHT). Oral finasteride 1 mg reduces serum DHT by approximately 70% within 24 hours of the first dose, and the 5 mg BPH dose suppresses DHT by around 70 to 90% at steady state. [1]

Absorption and Metabolism

Finasteride is absorbed rapidly after oral ingestion, reaching peak plasma concentration (Cmax) in roughly 1 to 2 hours. Bioavailability averages around 63% and is not meaningfully affected by food. The drug is metabolized primarily in the liver via cytochrome P450 3A4 (CYP3A4) into two inactive metabolites, which are then excreted in feces (57%) and urine (39%). [2]

Half-Life and Steady State

The plasma half-life of finasteride in men under 70 is approximately 5 to 6 hours, though the drug's pharmacodynamic effect on DHT suppression outlasts the plasma half-life considerably because of tight enzyme binding. Steady-state DHT suppression is maintained with once-daily dosing. [2]

Clinical Indications

The FDA approved finasteride 1 mg (Propecia) for androgenetic alopecia (male pattern hair loss) and finasteride 5 mg (Proscar) for symptomatic benign prostatic hyperplasia. A 2-year placebo-controlled trial (N=1,553) published in the Journal of the American Academy of Dermatology showed that finasteride 1 mg increased hair count by a mean of 107 hairs per 1-inch circle vs. A loss of 50 hairs in the placebo group. [3]

What NAC Is and How It Works

NAC (N-acetylcysteine) is the acetylated form of the amino acid L-cysteine and serves as the primary oral precursor to glutathione, the body's principal intracellular antioxidant. Clinicians use it in hospital settings intravenously to treat acetaminophen overdose, and in outpatient settings it is sold as an over-the-counter supplement for antioxidant support, respiratory mucolysis, and increasingly for PCOS-related insulin resistance. [4]

Glutathione Synthesis Pathway

After oral ingestion, NAC is deacetylated in the gut wall and liver to L-cysteine. L-cysteine then combines with glutamate and glycine to form glutathione via the gamma-glutamylcysteine synthetase pathway. This synthesis route does not involve cytochrome P450 enzymes at any step, which is a key mechanistic reason why NAC has minimal interaction potential with CYP-metabolized drugs like finasteride. [5]

Antioxidant and Anti-Inflammatory Effects

Beyond glutathione replenishment, NAC scavenges reactive oxygen species directly and modulates NF-kB inflammatory signaling. A 2023 meta-analysis in Antioxidants (N=1,004 participants across 14 RCTs) found that NAC supplementation significantly reduced malondialdehyde (MDA), a marker of lipid peroxidation, with a pooled standardized mean difference of -0.74 (95% CI: -1.01 to -0.46, P<0.001). [6]

Standard Doses Used in Research

Clinical trials have studied NAC at doses ranging from 600 mg once daily (mucolytic applications) up to 1,800 mg per day split into three doses (PCOS, psychiatric conditions). The FDA removed NAC from the dietary supplement "grandfathered" category in 2020, though enforcement has remained limited and it continues to be sold widely. [7]

The Interaction Question: Is There a Pharmacokinetic Problem?

No published pharmacokinetic study has identified a direct interaction between NAC and finasteride. The two agents use entirely separate metabolic machinery, which reduces the theoretical basis for any clinically meaningful drug-drug interaction.

CYP3A4 and NAC: No Overlap

Finasteride relies on CYP3A4 for hepatic metabolism. NAC does not inhibit or induce CYP3A4 at any dose that has been studied in humans. A 2004 pharmacokinetic study in the British Journal of Clinical Pharmacology evaluated NAC's effect on multiple CYP isoforms using probe substrates and found no clinically significant CYP inhibition at oral doses up to 1,200 mg/day. [8] Because NAC leaves CYP3A4 activity intact, finasteride's metabolism proceeds at its normal rate, and plasma DHT suppression should not be altered by concurrent NAC use.

Protein Binding: Minimal Concern

Finasteride is approximately 90% protein-bound in plasma. NAC is also partially protein-bound, raising a theoretical question about competitive displacement. In practice, displacement interactions require a drug to occupy a large fraction of the same binding sites simultaneously, and neither agent is present in concentrations that make this clinically likely. No empirical data suggest this is a real-world issue with this pair. [2]

Pharmacodynamic Overlap: Actually Potentially Complementary

The pathways targeted by finasteride (androgen synthesis) and NAC (redox homeostasis) do not oppose each other. Oxidative stress has been implicated in the miniaturization of hair follicles in androgenetic alopecia. A 2021 study in Dermatology and Therapy (N=60) found that men with androgenetic alopecia had significantly lower scalp tissue glutathione levels compared with controls (P<0.05). [9] Whether restoring glutathione via NAC adds measurable clinical benefit on top of finasteride's DHT suppression has not been tested in a head-to-head RCT, but there is no pharmacodynamic reason the two should interfere with each other.

NAC and Finasteride for Hair Loss: Is There Additive Benefit?

The question of whether NAC could add to finasteride's hair-preservation effect is biologically reasonable but currently speculative. Here is a working clinical framework for thinking through this combination.

Oxidative Stress as a Secondary Driver of Hair Loss

DHT-driven follicle miniaturization is the primary mechanism in androgenetic alopecia, but oxidative stress appears to be a secondary accelerant. Reactive oxygen species generated in the scalp microenvironment can trigger premature catagen (the regressing phase of the hair cycle) and apoptosis in follicular keratinocytes. Finasteride addresses the androgen axis. NAC, by replenishing glutathione, may address the oxidative axis. The two mechanisms are non-overlapping, meaning combined use has a plausible rationale. [9]

What the Literature Does (and Does Not) Show

No double-blind RCT has directly tested NAC plus finasteride for androgenetic alopecia. Several small studies have examined antioxidant supplementation alongside 5-alpha-reductase inhibitors in BPH patients (where oxidative stress in prostate tissue is a recognized co-factor), but none used NAC specifically at doses comparable to over-the-counter supplementation alongside 1 mg finasteride. The absence of a trial is not evidence of harm. It means the additive efficacy question remains open.

What Clinicians Generally Recommend

Clinicians at HealthRX who see patients combining the two agents generally advise continuing finasteride as prescribed without modifying the dose or timing, starting NAC at the lower end of the dose range (600 mg once daily with food), and reassessing after 3 months. If the patient tolerates both, dose escalation to 1,200 mg/day is reasonable for those using NAC for its antioxidant properties specifically.

NAC and Finasteride for BPH: A Separate Context

In the BPH setting, finasteride 5 mg/day shrinks the prostate by reducing DHT-driven growth. A 4-year trial (the PLESS study, N=3,040) showed finasteride reduced the risk of acute urinary retention by 57% and the need for surgical intervention by 55% compared with placebo. [10]

Oxidative Stress in Prostate Tissue

Oxidative stress contributes to prostate inflammation and may accelerate BPH progression. A 2019 study in Prostate (N=112) found that men with BPH had significantly elevated 8-hydroxydeoxyguanosine (8-OHdG), a DNA oxidative damage marker, in prostate biopsies compared with controls. [11] This creates a biological rationale for antioxidant support alongside 5-alpha-reductase inhibition.

NAC-Specific BPH Data

Dedicated NAC-plus-finasteride BPH trials do not yet exist in the primary literature. The indirect evidence from oxidative stress biomarker studies is suggestive but not confirmatory. Men with BPH who are already on finasteride 5 mg and wish to add NAC should inform their urologist, primarily so that any changes in LUTS (lower urinary tract symptoms) can be attributed correctly rather than because of known interaction risk.

Safety Profile: When Caution Is Actually Warranted

The combination is generally well tolerated, but certain clinical situations deserve closer attention.

Liver Enzyme Monitoring

Both NAC (at high doses) and finasteride undergo hepatic processing. Finasteride itself rarely causes hepatotoxicity; post-marketing surveillance data through the FDA MedWatch system show liver enzyme elevations as a rare adverse event. High-dose NAC (above 1,800 mg/day) taken chronically has been associated in isolated case reports with mild transaminase elevation. Men with pre-existing liver disease, those using alcohol heavily, or those on other hepatically metabolized drugs should have baseline liver function tests (LFTs) before starting either agent and recheck at 3 months. [12]

Renal Clearance

Finasteride's metabolites are partially renally excreted. NAC and its metabolites are also cleared renally. Men with eGFR below 30 mL/min/1.73 m² should discuss both agents with their nephrologist before combining them, not because of a drug-drug interaction per se, but because dosing adjustments for both agents may be appropriate in severe renal impairment. [2]

Side Effect Attribution

Finasteride carries a class-level risk of sexual side effects (decreased libido, erectile dysfunction, ejaculatory disorders) affecting roughly 3 to 4% of men in registration trials. NAC at standard doses most commonly causes nausea and GI upset, particularly when taken without food. If a patient starts both agents simultaneously and develops new symptoms, sequential discontinuation (stopping NAC first given its shorter tissue half-life) can help identify the source.

Dose Timing: Do You Need to Separate These Two?

No. There is no evidence-based requirement to separate the doses of finasteride and NAC in time. Because they use different metabolic pathways and do not compete for the same enzymes, transporters, or receptor sites, taking them together at the same time of day is pharmacologically acceptable. [8]

Many patients find it easier to take finasteride with their morning routine and NAC with a meal (to reduce GI side effects from NAC). That practical schedule works fine and happens to space them slightly, but the spacing is for GI comfort, not for any interaction-avoidance purpose.

Drug Interaction Database Ratings

Natural Medicines Comprehensive Database (the standard pharmacist reference for supplement-drug interactions) does not list a clinically significant interaction between NAC and finasteride as of the most recent available edition. The Lexicomp and Micromedex databases similarly do not flag this combination. An absence of a flagged interaction in these databases reflects the mechanistic logic described above: no shared CYP enzymes, no opposing pharmacodynamic targets, no competitive protein binding at clinically relevant concentrations.

What to Tell Your Prescriber

Transparency matters. Even when a combination is pharmacologically benign, your prescribing clinician needs a complete medication and supplement list to give accurate guidance. Before or when starting NAC alongside finasteride:

• List NAC on your medication reconciliation form by name and dose.
• Mention any other supplements you take, especially those with known CYP3A4 interactions (St. John's Wort, for example, is a potent CYP3A4 inducer that could meaningfully lower finasteride plasma levels, unlike NAC). [13]
• Request a baseline LFT panel if you plan to use NAC at 1,200 mg/day or above for more than 3 months.
• Report any new symptoms (GI, sexual, urinary) so they can be correctly attributed.

The American Urological Association's 2023 guideline on male LUTS/BPH states: "Patients should be counseled about the limited evidence base for dietary supplements in BPH management, and clinicians should document all supplement use as part of the medication history." [14]

Special Populations

Women Using Finasteride Off-Label

Finasteride 2.5 mg to 5 mg is sometimes prescribed off-label for female pattern hair loss. Women with PCOS who also take NAC should note that NAC has specific studied applications in PCOS (improving insulin sensitivity and ovulatory function). A 2018 Cochrane review (N=910 women across 10 RCTs) found NAC improved ovulation rates in PCOS compared with placebo, though it was inferior to metformin for this endpoint. [15] NAC's partial overlap with PCOS metabolic management does not create an interaction with finasteride, but the indication context is worth discussing with an endocrinologist or gynecologist.

Older Adults

Men over 70 metabolize finasteride more slowly; the half-life extends to approximately 8 hours in this age group. Age-related reductions in renal function may also slow NAC metabolite clearance. Starting at the lower end of both dose ranges and titrating slowly is sensible in this population.

Practical Takeaways by Clinical Scenario

| Scenario | Recommendation | |---|---| | Taking finasteride 1 mg for hair loss, want to add NAC 600 mg/day | Proceed; no dose timing restriction needed | | Taking finasteride 5 mg for BPH, want to add NAC 1,200 mg/day | Inform urologist; baseline LFTs if not recently done | | Pre-existing mild liver disease | Discuss with prescriber before adding either agent at higher doses | | eGFR <30 mL/min/1.73 m² | Nephrology consult before combining | | Female, off-label finasteride, PCOS, considering NAC | Discuss with prescribing clinician; NAC has PCOS-specific evidence worth evaluating separately | | Taking St. John's Wort alongside finasteride | Stop St. John's Wort first; this interaction (CYP3A4 induction) is clinically significant, unlike NAC |